JP2022531898A5 - - Google Patents

Info

Publication number
JP2022531898A5
JP2022531898A5 JP2021566160A JP2021566160A JP2022531898A5 JP 2022531898 A5 JP2022531898 A5 JP 2022531898A5 JP 2021566160 A JP2021566160 A JP 2021566160A JP 2021566160 A JP2021566160 A JP 2021566160A JP 2022531898 A5 JP2022531898 A5 JP 2022531898A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
patient
cancer
breast cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021566160A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531898A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/062743 external-priority patent/WO2020225375A1/en
Publication of JP2022531898A publication Critical patent/JP2022531898A/ja
Publication of JP2022531898A5 publication Critical patent/JP2022531898A5/ja
Ceased legal-status Critical Current

Links

JP2021566160A 2019-05-09 2020-05-07 転移性または進行性乳房がん患者において使用するための6-(2,4-ジクロロフェニル)-5-[4-[(3s)-1-(3-フルオロプロピル)ピロリジン-3-イル]オキシフェニル]-8,9-ジヒドロ-7h-ベンゾ[7]アヌレン-2-カルボン酸 Ceased JP2022531898A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP19305593.6 2019-05-09
EP19305593 2019-05-09
EP19305679 2019-05-28
EP19305679.3 2019-05-28
US201962945311P 2019-12-09 2019-12-09
US62/945,311 2019-12-09
PCT/EP2020/062743 WO2020225375A1 (en) 2019-05-09 2020-05-07 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients

Publications (2)

Publication Number Publication Date
JP2022531898A JP2022531898A (ja) 2022-07-12
JP2022531898A5 true JP2022531898A5 (https=) 2023-05-01

Family

ID=70681807

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021566160A Ceased JP2022531898A (ja) 2019-05-09 2020-05-07 転移性または進行性乳房がん患者において使用するための6-(2,4-ジクロロフェニル)-5-[4-[(3s)-1-(3-フルオロプロピル)ピロリジン-3-イル]オキシフェニル]-8,9-ジヒドロ-7h-ベンゾ[7]アヌレン-2-カルボン酸

Country Status (13)

Country Link
US (2) US20200352905A1 (https=)
EP (1) EP3965758A1 (https=)
JP (1) JP2022531898A (https=)
KR (1) KR20220006553A (https=)
CN (1) CN114173776A (https=)
AU (1) AU2020268762A1 (https=)
BR (1) BR112021022216A2 (https=)
CA (1) CA3146346A1 (https=)
IL (1) IL287805A (https=)
MX (1) MX2021013711A (https=)
SG (1) SG11202111979SA (https=)
TW (1) TW202110434A (https=)
WO (1) WO2020225375A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021003440A2 (pt) 2018-09-07 2021-05-18 Sanofi sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação
EP4037768B1 (en) 2019-10-01 2023-10-11 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
AU2020399168A1 (en) 2019-12-09 2022-07-28 Sanofi Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司(alpelisib)與6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯啶-3-基]氧苯基]-8,9-二氫-7h-苯并[7]輪烯-2-羧酸之組合
TW202233572A (zh) 2020-10-19 2022-09-01 法商賽諾菲公司 新穎之經取代的6,7-二氫-5h-苯並[7]輪烯衍生物,其製備方法及其治療用途
WO2022084280A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
WO2022106711A1 (en) * 2020-11-23 2022-05-27 Sanofi Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
CN117042771A (zh) * 2021-03-09 2023-11-10 伊莱利利公司 使用serd给药方案的组合治疗癌症的方法
TWI837605B (zh) * 2021-03-09 2024-04-01 美商美國禮來大藥廠 使用serd組合給藥方案治療癌症之方法
TW202400136A (zh) * 2022-03-13 2024-01-01 法商賽諾菲公司 以安森司群(amcenestrant)治療乳癌
TW202543650A (zh) 2024-03-08 2025-11-16 美商海爾達醫療運營公司 異雙官能化合物及其在治療疾病中之用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19833786A1 (de) * 1998-07-18 2000-01-20 Schering Ag Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
EP3089747A1 (en) * 2013-12-06 2016-11-09 F. Hoffmann-La Roche AG Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
KR20250152679A (ko) * 2015-04-29 2025-10-23 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
LT3386500T (lt) * 2015-12-09 2022-12-27 The Board Of Trustees Of The University Of Illinois Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu
EA034994B1 (ru) 2016-02-15 2020-04-15 Санофи 6,7-дигидро-5h-бензо[7]аннуленовые производные в качестве модуляторов эстрогеновых рецепторов
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid

Similar Documents

Publication Publication Date Title
JP2022531898A5 (https=)
EP4096671B1 (en) Combination therapy for treating abnormal cell growth
JP7578643B2 (ja) 異常な細胞成長を処置するための方法および組成物
CA3080197C (en) Formulations of a compound modulating kinases
JP2022172480A (ja) 治療組成物、組み合わせ、及び使用方法
US8383607B2 (en) Perifosine and capecitabine as a combined treatment for cancer
US20230201198A1 (en) Methods of treating abnormal cell growth
JP2018514511A (ja) 乳房障害とエストロゲン関連障害の処置のための組成物と方法
JP2022540421A5 (https=)
JP2012522837A5 (https=)
TW202333675A (zh) 用於治療癌症之組合療法之用途
JP2003533485A5 (https=)
JP2014512355A5 (https=)
JP2023522716A5 (https=)
TW201300107A (zh) 組合療法
JP2023522415A5 (https=)
WO2024017316A1 (zh) 药物组合产品以及组合疗法
JP2022177119A5 (https=)
TW200306185A (en) Combinations comprising EPOTHILONES and anti-metabolites
JP2024506385A5 (https=)
JP2023501317A5 (https=)
AU2009219464B2 (en) Combination anti-cancer agents
JP2024506347A5 (https=)
CN104936585A (zh) 包括苯肾上腺素和扑热息痛的组合药剂
RU2021136115A (ru) 6-(2,4-дихлорфенил)-5-[4-[(3s)-1-(3-фторпропил)пирролидин-3-ил]оксифенил]-8,9-дигидро-7h-бензо[7]аннулен-2-карбоновая кислота для применения у пациентов с метастатическим или распространенным раком молочной железы